Neoplasms

Skin and Connective Tissue Diseases

All Conditions

Breast Neoplasms

Breast Diseases

Skin Diseases

Bone Density Conservation Agents

Antineoplastic Agents

All Drugs and Chemicals

Tamoxifen

Aromatase Inhibitors

Eligible participants will begin treatment with flibanserin 100 mg orally daily at bedtime for 24-36 weeks and followed for a total of 52 weeks.

Flibanserin Pill

Shari Goldfarb, MD

The purpose of this study is to determine if it is feasible for women to take both Flibanserin and tamoxifen for the duration of the study. This study is also trying to find out if Flibanserin improves or has any effect on hyposexual desire disorder/HSDD in women who are taking tamoxifen for breast cancer.

A Study of Flibanserin in Breast Cancer Survivors on Tamoxifen or Aromatase Inhibitors

A Feasibility Study of Flibanserin in Breast Cancer Survivors on Tamoxifen and Aromatase Inhibitors

To evaluate the feasibility defined as the treatment discontinuation rate of flibanserin for 24 weeks due to toxicity, withdrawal of consent or other events related to tolerability.

The AE reporting period begins on the first day of study drug administration and continues until 4 weeks after the patient has taken the last dose of study drug. AE's will be evaluated using CTCAE v 4.

Memorial Sloan Kettering Cancer Center

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
A Study of Flibanserin in Breast Cancer Survivors on Tamoxifen or Aromatase Inhibitors	NCT03707340	Breast Cancer Hyposexual Desi...	Flibanserin Pil...	21 Years -	Memorial Sloan Kettering Cancer Center
A Study of Flibanserin in Breast Cancer Survivors on Tamoxifen or Aromatase Inhibitors	NCT03707340	Breast Cancer Hyposexual Desi...	Flibanserin Pil...	21 Years -	Memorial Sloan Kettering Cancer Center

Spots Global Cancer Trial Database for hyposexual desire disorder